Title
Relapsing polychondritis with features of dementia with Lewy bodies.

Permalink
https://escholarship.org/uc/item/6t7008hg

Journal
Acta neuropathologica, 112(2)

ISSN
0001-6322

Authors
Head, Elizabeth
Starr, Arnold
Kim, Ronald C
et al.

Publication Date
2006-08-01

DOI
10.1007/s00401-006-0098-0

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
CASE REPORT

Relapsing polychondritis with features of dementia with Lewy bodies

Elizabeth Head · Arnold Starr · Ronald C. Kim · Anna Parachikova · Genaro E. Lopez · Malcolm Dick · David H. Cribbs

Received: 8 March 2006 / Revised: 7 June 2006 / Accepted: 7 June 2006 / Published online: 11 July 2006
© Springer-Verlag 2006

Abstract We describe a 72-year old man with clinical features suggestive of dementia with Lewy bodies (DLB) who proved neuropathologically to have degeneration induced by relapsing polychondritis (RP), an autoimmune inflammatory disorder of cartilaginous tissues. There was lymphocytic infiltration of the leptomeninges, perivascular cuffing, reactive astrocytosis, and activation of microglia in multiple brain areas all consistent with an immunologically mediated process. There was widespread neuronal loss within the hippocampus, entorhinal cortex, and amygdala as well as diffuse myelin pallor of cortical pathways. Elevated levels of complement proteins and endothelial markers of inflammation were observed, which are similar to previous reports in DLB. This study demonstrates that qualitatively similar inflammation-associated neurodegeneration is present in widespread regions of the brain in a RP case presenting clinically as DLB.

Keywords Complement · Hippocampal cell loss · Neuroinflammation · White matter degeneration

Introduction

Initially described in 1923 by Jaksch-Wartenhorst [23], relapsing polychondritis (RP) is an autoimmune disorder affecting connective tissues and most commonly leads to inflammation-induced deformity of the ear or nasal cartilage [31, 33, 49, 52]. However, clinical disease at other sites is common and may include arthritis or pulmonary, renal, dermatologic, cardiovascular, or neurologic manifestations [24]. Typically RP is diagnosed on the basis of clinical signs [31], and 33–50% of patients develop autoantibodies against type II collagen [12] and, less frequently, against collagen IX and XI, and matrilin-1 [16]. Tissue pathology typically includes infiltration by T lymphocytes and plasma cells and accumulation of granular deposits of immunoglobulins and complement, suggesting the presence of immune complexes [16, 49]. RP is frequently associated with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, progressive systemic sclerosis, and other rare connective tissue diseases [33]. On the other hand, inflammation has been considered to be a possible contributing factor in the development of neurodegeneration in a variety of dementing disorders [1].

We describe a 72-year old man with RP who died after a 3-year illness characterized by clinical features suggestive of dementia with Lewy bodies (DLB). He did not respond to anticholinesterase or dopaminergic agents and refused corticosteroid therapy. The dementia was marked by a fluctuating course, recurrent visual
hallucinations, and parkinsonism [32]. Neuropathologically, he proved to have neither DLB nor Alzheimer disease (AD) but, instead, showed multifocal, predominantly leptomeningeal infiltration by inflammatory cells and brain degeneration that we believe was immunologically mediated and associated with the RP that he suffered from during life.

Case report

A right-handed, 71-year old Caucasian male with 14 years of education presented at the University of California, Irvine–Alzheimer’s Disease Research Center (UCI-ADRC) in early November 2001 with complaints of memory loss, language difficulties, abnormal motor behavior, and visual hallucinations as well as depression, agitation, and insomnia. His family history was significant for memory problems for both his mother (died at 95 years of age) and his father (died at 82 years of age) but the cause of these difficulties was not established. His siblings did not show signs of dementia and both were deceased (sister age 74 and brother age 68 years). According to his wife, he was in good health until April 2000, at the age of 69 years, when he became acutely vertiginous immediately after colonoscopy. The family reported that dizziness and balance problems persisted and evolved to include other symptoms, including forgetfulness, tremor, and pains in the lower extremities. A neurological examination in November 2000 was interpreted as normal, with no sensory, motor, or gait abnormalities. Within a few months there were rapid shifts in both mood and other cognitive fluctuations including orientation, recent memory, and recognizing familiar locations (e.g., houses on his street).

Fourteen months later the patient had a motor vehicle accident after becoming confused and failing to stop the car. A CT scan of the brain performed immediately following the accident revealed global atrophy and two small bilateral frontal subdural hygromas, which were thought to not be significant contributing factors to his cognitive decline. The right ear was noted to be swollen with tissue hemorrhages. The mini-mental status examination (MMSE [13]) score was in the moderately demented range (17/30). He was started on Aricept (Donepezil) but continued to decline mentally. In April 2001 he developed daily visual hallucinations (bugs and bright lights), and on occasion, “visions of bad people killing people” that subsequently became less frequent and eventually disappeared. A SPECT scan performed near the end of April 2001 showed significant cortical atrophy with decreased perfusion within cortical grey matter, particularly in the left occipital–parietal region.

In June 2001, motor and language impairments developed. The spouse reported that he was depressed and that he would frequently fall. On examination he expressed concern about these changes, had few spontaneous movements, maintained a fixed “smile” and blinked only occasionally. His speech was marked by paraphasias and perseverations. He was unable to spell and his writing was slowed and incomprehensible. The cranial nerve examination showed absence of upward gaze. When he was asked to move his arms, a rhythmic tremor appeared accompanied by sudden irregular brief jerks consistent with myoclonus. His gait was stiff without associated arm movements but was not festinating nor was cogwheeling observed on testing muscle tone in the arms. Tendon reflexes were hypactive and the plantar responses were flexor. There were bilateral grasp responses present. He demonstrated fixed dystonic posturing of the arms. Motor and reflex abnormalities were consistent with both frontal and extrapyramidal motor disorders. Sinemet (25–50 mg bid) was administered without benefit. The findings of dementia accompanied by extrapyramidal signs (slowness of movement, tremors, repeated falls) and unresponsive to Sinemet suggested a diagnosis of DLB. Bilateral deformities of the auricles consistent with RP were also noted (Fig. 1), but biopsy of the ear for confirmation of the diagnosis was refused.

The cognitive disorder progressed and 3 months later, he had to be evaluated using the severe impairment battery (SIB [37]) where his score was 73/100. The patient’s lowest scores occurred on tasks involving praxis, orientation, language, and recent memory, while visual-spatial and constructional skills remained relatively preserved. Neurological signs had worsened to include a bilateral resting tremor, bradykinesia, bilateral cogwheeling, and abnormal postural balance. Bilateral myoclonus and gait impairments were also observed.

His rapidly progressive dementia, fluctuating course, visual hallucinations, and extrapyramidal motor signs were thought to be consistent with a diagnosis of possible DLB. Table 1 summarizes features suggestive of DLB according to the criteria of McKeith et al. [32]. Three years after the onset of cognitive dysfunction and 8 months after his last neuropsychological evaluation, he died of pneumonia.

Materials and methods

Brain tissue procedure

The brain, which was collected within 3.6 h of death, was sectioned through the midline. The right cerebral
The brain at autopsy weighed 1,271 g. As seen in coronal section, there was striking atrophy of the temporal lobe, with prominent widening of the sylvian fissure, enlargement of the temporal horn of the lateral ventricle, and shrinkage of the hippocampus (Fig. 2).

Microscopically, neuritic plaque formation was absent within most of the cerebral neocortex, hippocampus, and amygdala; it was observed in mild to moderate degree only within the calcarine/pericalcarine and transentorhinal cortex. Neurofibrillary degeneration, which was judged overall to be of stage I severity by Braak and Braak criteria, was absent at all of the aforementioned sites except for the transentorhinal region, where it was present in trace amounts. According to NIA/Reagan criteria, therefore, the likelihood that dementia was due to Alzheimer disease was low [10].

B-cell, T-cell, and complement proteins were used to characterize the type and extent of inflammation. Standard immunohistochemical procedures were used [19]. Control experiments included elimination of primary or secondary antibodies, which all were negative.

## Results

### Neuropathology

The brain at autopsy weighed 1,271 g. As seen in coronal section, there was striking atrophy of the temporal lobe, with prominent widening of the sylvian fissure, enlargement of the temporal horn of the lateral ventricle, and shrinkage of the hippocampus (Fig. 2).

Microscopically, neuritic plaque formation was absent within most of the cerebral neocortex, hippocampus, and amygdala; it was observed in mild to moderate degree only within the calcarine/pericalcarine and transentorhinal cortex. Neurofibrillary degeneration, which was judged overall to be of stage I severity by Braak and Braak criteria, was absent at all of the aforementioned sites except for the transentorhinal region, where it was present in trace amounts. According to NIA/Reagan criteria, therefore, the likelihood that dementia was due to Alzheimer disease was low [10].
The concentration of neuromelanin-bearing neurons within the substantia nigra and locus ceruleus was only mildly reduced, with only minimal amounts of extraneuronal neuromelanin and with no evidence of neurofibrillary degeneration or Lewy body formation. Lewy bodies and Lewy neurites were also absent from the dorsal motor nucleus of the vagus, amygdala, substantia innominata, hippocampal pyramidal layer, subiculum, entorhinal/transentorhinal region, and rostral cingulate and temporal neocortex.

Mild patchy but widely distributed foci of leptomeningeal infiltration by CD4- and CD8-immunoreactive lymphocytes were observed that occasionally extended into the walls of veins (Fig. 3a). Frank vasculitis was also occasionally encountered (Fig. 3a, inset). CD68-immunoreactive macrophages were also moderately abundant (Fig. 3d) and could be seen in places to extend for short distances into perivascular Virchow–Robin spaces. Subpial reactive astrocytosis and microvacuolar degeneration within layer two were observed in patchy distribution within frontal, temporal, caudal cingulate, and entorhinal cortex. Severe nerve cell loss and reactive astrocytosis were noted within the hippocampal pyramidal layer [especially within CA1 and CA3, with striking sparing of the subiculum (Fig. 3f)],

**Table 2** Antibodies used in immunohistochemical experiments

| Antibody | Marker | Host | Source |
|----------|--------|------|--------|
| Complement pathway | C1q | Classical complement pathway | Polyclonal | Dako, Temcula, CA |
|        | C4d | Classical complement pathway | Monoclonal | Quidel Corp., San Deigo, CA |
| Effector enzymes | C3b | Alternative pathway | Monoclonal | Quidel Corp., San Deigo, CA |
|        | iNOS | Inducible Nitric oxide synthase | Polyclonal | Chemicon International, Temecula, CA |
| Lymphocytes | CD3 | T-lymphocytes | Monoclonal | Novocastra Laboratories, Ltd., UK |
|        | CD4 | T-lymphocytes | Monoclonal | Novocastra Laboratories, Ltd., UK |
|        | CD8 | T-lymphocytes | Monoclonal | Novocastra Laboratories, Ltd., UK |
|        | CD40 | B-cells | Monoclonal | Novocastra Laboratories, Ltd., UK |
| Gliosis | Anti-GFAP | Astrocytosis | Polyclonal | Dako, Temcula, CA |
|        | LN-3 | Microglial activation | Monoclonal | ICN Biomedicals, Aurora, Ohio |
| AD pathology | 6E10 | Senile plaques | Monoclonal | Signet Laboratories, Dedham, MA |
|        | AT8 | Neurofibrillary tangles | Monoclonal | Pierce Biotechnology, Rockford, IL |
| Markers used for final neuropathology diagnosis | Anti-ubiquitin | Lewy bodies | Polyclonal | Dako, Temcula, CA |
|        | Alpha-synuclein | Lewy bodies | Polyclonal | Chemicon International, Temecula, CA |
|        | Anti-beta-amyloid | Senile plaques | Monoclonal | Dako, Temcula, CA |
|        | Anti-tau | Neurofibrillary tangles | Polyclonal | Dako, Temcula, CA |
|        | CD68 | Microglial activation | Monoclonal | Dako, Temcula, CA |

**Fig. 2** Photograph of a coronal section showing striking atrophy of the temporal lobe, with prominent widening of the sylvian fissure (arrow), enlargement of the temporal horn of the lateral ventricle (asterisk), and shrinkage of the hippocampus (arrowhead)
entorhinal cortex, and amygdala. Diffuse loss of myelinated axons, reactive astrocytosis, and proliferation of microglial cells were observed (Fig. 3g–i, respectively), particularly within those regions adjoining sites of severe damage to grey matter.

Glial activation and complement protein immunohistochemistry

**Hippocampus**

Immunostaining of the left hippocampus for MHC-Class II (LN-3; Fig. 4a), glial acidic fibrillary protein (GFAP) (Fig. 4b), and C1q (Fig. 4c), the first component of the classical pathway complement cascade, revealed extensive glial activation along with significant neuronal labeling for C1q. In addition, immunostaining for another complement factor, C4d, was extensive within both neurons and blood vessels (Fig. 4d). C4d immunoreactivity appeared as a diffuse cloud of staining in white matter of the hippocampus and, in particular, within the outer molecular layer of the dentate gyrus (Fig. 4f) suggesting an association with entorhinal cortex neuron terminals. iNOS immunolabeling revealed blood vessel labeling (Fig. 4e).

**Frontal cortex**

Immunostaining of the left frontal cortex showed gliosis that was as extensive as observed in the hippocampus (Fig. 4g, h). C1q immunoreactivity was limited to light diffuse staining with neurons remaining immunonegative for C1q (Fig. 4i). C4d immunostains showed extensive white matter labeling (Fig. 4j). iNOS immunoreactivity was observed in association with blood vessels in the frontal cortex, as it was in the hippocampus (Fig. 4k).
Discussion

In the current study we describe a patient with RP in whom the combination of dementia, visual hallucinations, and motor abnormalities suggested a diagnosis of DLB. Neuropathologically, however, he proved to have neither DLB nor AD. Instead there was severe nerve cell loss within the hippocampus, entorhinal cortex, and amygdala that was associated with patchy but widespread lymphocytic infiltration, predominantly within the leptomeninges. Further immunohistochemical studies revealed significant neuronal labeling with antibodies against C1q in the left hippocampus corresponding to areas of cell loss in the right hippocampus. Other markers of inflammation, used to identify activated microglia and other proteins involved in the complement pathway were all increased. Inflammation within the hippocampus and cerebral cortex could represent a neurobiological basis for the clinical signs of dementia, hallucinations, and a motor disorder.

There are few neuropathological studies of patients with RP and clinical signs of dementia in the literature. A profile of inflammation similar to our case was noted in a younger patient (52 years) who developed RP along with cognitive decline [45]. The patient died at the age of 57 years and microscopically the brain showed diffuse vasculitis affecting medium and small arteries and veins in at least 60% of the areas sampled. Some perivascular areas showed significant infiltration by lymphocytes into the parenchyma. “Burned out”

Fig. 4 Microglial activation, astrogliosis, and other markers of inflammation in area CA1 of the hippocampus. Extensive microglial activation (LN-3) (a) and astrocytosis (GFAP) (b) was observed along with an accumulation of C1q (c) and C4d (d) within neurons of the hippocampus. iNOS was also present at high levels in association with blood vessels (e). Within the white matter of the hippocampus, a dark diffuse cloud associated with the outer molecular layer of the dentate gyrus was positive for C4d (f). In the frontal cortex, extensive microglial activation was observed in the case (g). The extent of astrocytosis was not as extensive as observed in the hippocampus (h). In contrast to the hippocampus, virtually no neuronal C1q labeling in the frontal cortex (i). As in the hippocampus, C4d was extensive in the white matter of the frontal cortex (j) and iNOS immunolabeling was associated with blood vessels (k). Sections counterstained with cresyl violet. Bar = 100 μm
inflammatory lesions were noted in the frontal and temporal cortex. Significant necrotizing vasculitis and perivascular gliosis were noted in the medial thalamus and around the 4th ventricle. The hippocampus and in particular, the fascia dentata showed changes consistent with hypoxia, and there was inflammation in the fornix with scattered necrosis and vasculitis. The authors concluded that the patient had asceptic meningitis [45]. Hippocampal damage was common in both the current study and in this previous case and could account for the memory dysfunction observed in both patients.

In vivo imaging may be useful for detecting neurological inflammation due to RP and there are three previous case studies in addition to the current report describing MRI or CT studies. In one report, a 57-year old male with RP showed high intensity “spots” bilaterally in hippocampus and amygdala and the left paraventricular white matter, which progressed over time to involve also the caudate and putamen. This patient developed dementia with severe recent memory impairment, anxiety, and a mild depression [36]. A second case study reported multifocal gray and white matter high intensities in a 36-year old male with RP, and the authors suggested that it was related to cerebral arteritis [30]. A third 72 year old subject with a 20 year course of the disease and tremor revealed multiple spotted, confluent signal intensities consistent with cerebral angiitis on MRI [11].

In our studies, multiple markers of neuroinflammation, microglial activation (HLA-DR), and activation of the complement pathways (C1q, C3b, C4d) were observed in the hippocampus. C4d labeling was also observed in frontal cortical neurons and in the white matter. In contrast, in the frontal cortex, C1q labeling was virtually absent. It is likely that the signs of neuroinflammation observed may have led to a dementia that resembled DLB. However, there are few studies examining neuroinflammation in DLB, with little consensus as to whether inflammation is a consistent feature of the disease [22, 27, 43, 48]. Complement proteins in the brain have been observed within Lewy bodies in DLB [22, 48] and in some [51] but not all studies [42] of Lewy bodies in Parkinson’s disease. The extent of microglial activation in the cortex of DLB cases is variably reported as being comparable to controls [43] or increased relative to controls [27, 28]. Inclusion of DLB cases with AD pathology can contribute to some of the variability in the observation of activated microglia [43]. However, cytokine production by activated microglial cells in the hippocampus of DLB cases is significantly higher than controls and may account for memory deficits observed in this form of dementia [21]. Thus there is some evidence of overlap in the neuropathology observed in this study and in other reports of DLB with respect to inflammation, but more direct studies are necessary.

In the case presented here, RP is likely to be the cause of the meningoencephalitis, vasculitis, activation of the complement cascade, astrocytosis, and microglial proliferation, leading to severe hippocampal neuron loss that undoubtedly accounted for the patient’s dementia. A significant subset of patients with autoimmune diseases affecting connective tissue, including RP, also develop neurological disorders such as depression, dementia, psychosis, seizures, and tremors [33]. In RP the incidence of neurologic involvement is between 3 and 9.7% [52] with the most common features being headache, confusion, and altered levels of consciousness [4, 6, 17, 39, 45, 50]. Seizures, ischemic strokes, subarachnoid hemorrhage, dementia, cerebellar, and cranial nerve signs have all been observed in RP and may be associated with either cerebral vasculitis [33] or meningitis [4, 17, 26]. Moreover, CNS vasculitis may develop in the absence of detectable systemic vasculitis [33].

Molecular mechanisms of inflammation

The relative contributions of the adaptive and the innate immune systems to the neurodegeneration in the current case are difficult to determine because autoantibodies were not analyzed and measurements of T cell reactivity to previously described self-antigens such as collagen II and matrilin-1, were not performed. The fact that animal models of RP are only now becoming available has hampered the interpretation of the events that lead to secondary sites of inflammation that may lack the putative self-antigens that trigger the primary autoimmune event in cartilaginous tissues. However, two scenarios should be considered as likely possibilities for the CNS involvement in this case. The first involves expression of the protein antigens of the initial inflammatory response in RP, such as collagen or matrilin-1, in the cerebrovasculature. Presumably, the deposition of these antigens in the basement membrane of the leptomeninges and parenchymal cerebrovasculature provide sites for either autoantibody–antigen immune complexes to activate complement or T cell–mediated attack on vascular elements.

The second scenario is antigen-independent and requires only that activated T cells infiltrate into the CNS due to an innate inflammatory response in the brain. This may be triggered by peripheral inflammation, which is a likely possibility in RP [8, 25, 41, 47]. Alternatively, injury or infection in the cerebrovasculature or brain
parenchyma can activate innate immune responses, which can then be propagated in wave-like fashion to adjacent tissue also resulting in T cell infiltration [2, 20, 34, 35, 38]. Regardless of the specific inflammatory mechanisms involved in the activation of both the innate immune responses and the recruitment and activation of the T cells in the CNS in this case, management of the initial presentation of the RP might have prevented the onset of neuropathology and clinical dementia.

Several RP patients described in the literature with neurological signs responded well to immunosuppressive therapy. In one case, oral prednisolone (60 mg/day) treatment led to improved cognitive function (MMSE score increased from 23 to 29 out of 30) [36]. In a second case report, a 58-year old woman presenting with confusion and visual hallucinations, disorientation with respect to place and time, some motor facial weakness and gait ataxia in parallel with RP also responded well to dapsone treatment [46]. Treatment with immunosuppressive agents may be used to reduce inflammation in tissues affected by relapsing polychondritis. However, the current patient’s age (early 70s) and dementia argued against the aggressive use of steroids. In a recent report, two patients with RP and memory dysfunction and other signs of dementia responded to methylprednisone pulse therapy and showed significant improvement. However, memory difficulties could not be fully reversed. The findings in our case suggest that neuroinflammation led to neuron loss within the hippocampus, which would have resulted in lasting memory impairment [14]. The literature suggests that RP, if not aggressively treated, may be followed by inflammatory involvement of other tissues [33, 52].

There are several other neurodegenerative diseases or disorders involving the immune system that may mimic DLB clinically in a manner similar to that described in the current study. For example, parkinsonian symptoms and dementia can be observed in progressive supranuclear palsy [40], corticobasal degeneration [3] and other types of parkinsonism-plus syndromes [9]. Further, Creutzfeldt–Jakob (CJD) disease can also be associated with atypical parkinsonian features [29], and patients with familial CJD may exhibit both parkinsonism and hallucinations [15]. Autoimmune disorders (e.g., multiple sclerosis) [7] or inflammatory diseases may lead to a rapid and progressive dementia with movement abnormalities [5, 18, 44]. Thus, RP may be another potentially reversible autoimmune disease that is associated with DLB-like dementia.

Acknowledgments Funding supported by ADRC P50 AG16573, P50 AG000658, NIA-Ag-20241 and NINDS-NS50895 (DHC). We would also like to extend our gratitude to the patient and his family for their assistance in the study.

References

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebig BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue LF, Mraak R, Mackenzie IR, McGregor PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salamon C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muyswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease: neuroinflammation working group. Neurobiol Aging 21:383–421
2. Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23:7922–7930
3. Belfor N, Amici S, Boxer AL, Kramer JH, Gorno-Tempini ML, Rosen HJ, Miller BL (2006) Clinical and neuropsychological features of corticobasal degeneration. Meach Ageing Dev 127:203–207
4. Berg AM, Kasznica J, Hopkins P, Simms RW (1996) Relapsing polychondritis and aseptic meningitis. J Rheumatol 23:567–569
5. Bornke C, Heye N, Buttnet T (1999) Rapidly progressive dementia. Lancet 353:1150
6. Brod S, Booss J (1988) Idiopathic CSF pleocytosis in relapsing polychondritis. Neurology 38:322–323
7. Calabrese P (2006) Neuropsychology of multiple sclerosis—an overview. J Neurol 253(Suppl I):10–15
8. Chakravarty S, Herkenham M (2005) Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci 25:1788–1796
9. Christine CW, Aminoff MJ (2004) Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am J Med 117:412–419
10. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the post mortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18:1–2
11. Dreher A, Aigner J, Fuchshuber S, Kastenbauer E (2000) Relapsing polychondritis: a course over 20 years with cerebral involvement. Arch Otalaryngol Head Neck Surg 126:1495–1498
12. Foidart JM, Abe S, Martin GR, Zizic TM, Barnett EV, Lawley TJ, Katz SI (1978) Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 299:1203–1207
13. Folstein MF, Folstein SE, McHugh PR (1975) The Mini-mental state: a practical method for grading the cognitive status of patients for the clinician. J Psychiatry Res 12:189–198
14. Fuji H, Tsukey O, Hashimoto K, Nakajima M, Yamada T (2004) Non-herpetic limbic encephalitis associated with relapsing polychondritis. J Neurol Neurosurg Psychiatry 75:1646–1647
15. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66:213–239
16. Gergely P Jr, Poor G (2004) Relapsing polychondritis. Best Pract Res Clin Rheumatol 18:723–738
17. Hanslik T, Wechsler B, Piette JC, Vidalhuet M, Robin PM, Godet P (1994) Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 12:539–541
18. Harkness KA, Coles A, Pohl U, Xuereb JH, Baron JC, Lennox GG (2004) Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy. Eur J Neurol 11:59–62
19. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribs DH (2001) Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol Dis 8:252–265
20. Hickey WF (2001) Basic principles of immunological surveillance of the normal central nervous system. Glia 36:118–124
21. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005) Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol (Berl) 109:141–150
22. Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K (2000) Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry. Neurosci Lett 286:69–73
23. Jakseh-Wartenhorst R (1923) Polychondropathia. Wein Arch 51:614–617
24. Kent PD, Michet CJ Jr, Luthra HS (2004) Relapsing polychondritis. Curr Opin Rheumatol 16:56–61
25. Konsman JP, Parnet P, Dantzer R (2002) Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25:154–159
26. Kothare SV, Chu CC, VanLandingham K, Richards KC, Hosford DA, Radtke RA (1998) Migratory leptomeningeal inflammation with relapsing polychondritis. Neurology 51:193–100
27. Mackenzie IR (2000) Activated microglia in dementia with Lewy bodies. Neurology 55:132–134
28. Mackenzie IR (2001) Cortical inflammation in dementia with Lewy bodies. Arch Neurol 58:519–520
29. Maltete D, Guyant-Marechal L, Mihout B, Hannequin D (2001) Movement disorders and Creutzfeldt–Jakob disease: a review. Parkinsonism Relat Disord 12:65–71
30. Massry GG, Chung SM, Selhorst JB (1995) Optic neuropathy, headache, and diplopia with MRI suggestive of cerebral arteritis in relapsing polychondritis. J Neuropathologem 15:171–175
31. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM (1976) Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55:193–215
32. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Nimsky C, Lopez OL, Carlos Machado J, O’Brien J, Playfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28
33. Nadeau SE (2002) Neurologic manifestations of connective tissue disease. Neurol Clin 20:151–178, vi
34. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124:2203–2214
35. Nguyen MD, Julien JP, Rivest S (2002) Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 3:216–227
36. Ohta Y, Nagano I, Niyya D, Fujioka H, Kishimoto T, Shoji M, Abe K (2004) Nonparaneoplastic limbic encephalitis with relapsing polychondritis. J Neurol Sci 220:85–88
37. Panisset M, Roudier M, Saxton J, Boller F (1994) Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 51:41–45
38. Perry VH, Newman TA, Cunningham C (2003) The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 4:103–112
39. Ragnaud JM, Tahbaz A, Morlat P, Sire S, Gin H, Albertin J (1996) Recurrent aseptic purulent meningitis in a patient with relapsing polychondritis. Clin Infect Dis 22:374–375
40. Rampello L, Butta V, Raffaele R, Vecchio I, Battaglia G, Cornaci G, Alvano A (2005) Progressive supranuclear palsy: a systematic review. Neurobiol Dis 20:179–186
41. Rivest S (2003) Molecular insights on the cerebral innate immune system. Brain Behav Immun 17:13–19
42. Rozemuller AJ, Eikelenboom P, Thielemans W, Jansen Steur EN, de Vos RA (2000) Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol (Berl) 100:701–708
43. Shepherd CE, Thiel E, McCann H, Harding AJ, Halliday GM (2000) Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch Neurol 57:817–822
44. Spiegel J, Hellwig D, Becker G, Muller M (2004) Progressive dementia caused by Hashimoto’s encephalopathy—report of two cases. Eur J Neurol 11:711–713
45. Stewart SS, Ashizawa T, Dudley AW Jr, Goldberg JW, Lidsky MD (1988) Cerebral vasculitis in relapsing polychondritis. Neurology 38:150–152
46. Sundaram MB, Rajput AH (1983) Nervous system complications of relapsing polychondritis. Neurology 38:150–152
47. Thibeault I, Lafortune N, Rivest S (2001) Regulation of the gene encoding the monocyte chemoattractant protein 1 (MCP-1) in the mouse and rat brain in response to circulating LPS and proinflammatory cytokines. J Comp Neurol 434:461–477
48. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K (2001) Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 184:71–75
49. Tremtham DE, Le CH (1998) Relapsing polychondritis. Ann Intern Med 129:114–122
50. Wasserfallen JB, Schaller MD (1992) Unusual rhombencephalitis in relapsing polychondritis. Ann Rheum Dis 51:1184
51. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 84:100–104
52. Zeuner M, Straub RH, Rauh G, Alberti ED, Scholmerich J, Lang B (1997) Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 24:96–101